DNA - Falling WedgeIt`s in our DNA to create reliable and objective analysis for our dear followers, and we will continue doing so.
We can see a falling wedge occurring on this chart, and we therefore expect a move to the upside.
Also the RSI has shown bullish divergence lately.
We will wait for a breakout of the trend, to take our long position.
More details are shown on the chart.
Biotech
The Future of Crypto MarketCap: TA to Navigating the 2030 AgendaGreetings fellow traders and investors,
The world events of the past year have had a profound impact on the global economy, and the crypto market has not been immune to these effects. As we move forward into the next period of capitalization, it is important to take a closer look at the current state of the crypto market and how it may be affected by the events unfolding around us.
In this analysis, I will examine some of the key factors that are likely to shape the crypto market in the coming months, including the ongoing COVID-19 pandemic, geopolitical tensions, and the transition to a digital economy. I will also explore some of the potential opportunities and challenges that traders and investors may encounter in this dynamic and rapidly evolving landscape.
Whether you are a seasoned trader or a newcomer to the crypto market, I believe that this analysis will provide you with valuable insights and actionable strategies for navigating the challenges and opportunities of the next capitalization period. So join me as we explore the future of the crypto market together, and let's uncover the hidden gems and potential profits that lie ahead.
Thank you for your attention, and let's get started!
We established great support at 750B, distribution was set, and we are now in an uptrend. This may be short lived after the events around us unfolding. The reactions of these events unfold slowly but will have a massive impact on the way we live.
It's no secret that this is modern warfare. There is a lot of uncertainty with our global currency, the USD. From it not becoming the figure of value of the Saudi Oil Barrel to China leaping into taking the throne.
It won't be long before news arouses over the "printing" of dollars from other countries such as Venezuela that they have officially figured out how to perfectly replicate it. This is pure speculation by the way. But it will play out. Banks will have "outages" which could last up to 3 days. Once that is survived, we may be presented with digitalizing the USD, and other world currencies.
How will this play out? Well, I am not Cryptodamous. But I will pretend that I am.
Uptrend: | Ends May 2023 | The speculation of uncertainty with the USD, people "Preparing" etc. will cause the market to go back to 1.5T, this will be short lived, and this is where the media will cover it, everyone will start to buy in again. This is your indicator to sell.
Downtrend: | May 2023 - Nov. 2023 | Within 33 days, a new plannedemic will start to become mainstream. What is it, not sure... Could be Anthrax. If it's Anthrax, well it will start off with Animals being infected by polluted soil and water. What can cause this? Of course, not train derailments leaking into our soil and rivers that interconnect with all major water sources for our (US) farmland. But we will be blamed for our carbon footprint.
The collateral damage will be a worldwide event. Food shortages, more control and possibly the first ever worldwide internet shortage. If what we are ingesting is infected, well then, we are also infected. All water above ground will be vulnerable. (Advice to buy land that you can tap a water well into)
This will last for 6-8 months. This will correct the market into what everyone was expecting. $12k BTC. (The potential to Flash wick into $7k exists - this will only last 2 hours).
Overall, this will place the total crypto market cap at $565B
The new Bull Cycle: | Nov. 2023 - Dec. 2025 | The introduction to a new form of control. Digitalizing the US dollar. The people will catch up to this soon as they come to realization that you have 0 privacy. Your money expires. All your whereabouts will be monitored. But most importantly, taxing our carbon footprint.
We are the first generation of humans to live life like this. This is new to everyone and although we can look at the past for the rise and fall of nations, we have the technology to break out of this system and treat Bitcoin as the true Digital "Gold."
All the above is not trading advice. Use TA to accurately make your trading decisions. Freedom doesn't have a price. But if it did, it's not worth less than 10 Trillion :) and people will pay 100 Trillion :)
$ZLAB: Interesting weekly base$ZLAB is an interesting biotech stock, with a couple potentially explosive catalysts during 2023. There's a nice weekly signal here indicating the stock is accumulated and ready to move up strongly over time.
Remember to size these names considering the extreme volatility that can occur after drug trial data comes out, or if they receive an FDA approval, etc.
Best of luck!
Cheers,
Ivan Labrie.
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
$SRNE needs time I think this has a range to stay within if its going to survive
Ideally it will stay within the 86 to 70 cent region, any further break down and we are in no mans land.
Even now we are in uncharted waters for this stock which has traditionally show much support and bounce at $1.45
Sub $1 can either be a steal or bad news bears. would DCA in this position and be optimistic for new developments in 2023
Young biotech leader $IMCR with good VCPImmunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases.
In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an initial position.
I liked the volatility contraction pattern and the bullish divergence with the 10-day ROC prior to the breakout, and now I'll wait for the follow through action to add to the position.
Lets wait and see.
$PRTG - (BIO) Small OS Small Float - Bottom in Plenty of UpsideCurrently trading mid 4's with a market cap under 100 million it's way to cheap for the Robust pipeline including the recent addition from Taurus adensonine pipeline
Structure
Shs Outstand 16.74M
Shs Float 10.13M
Expect Catalyst
Data readouts from pipeline
Research Pipeline
Merck, lead asset Port-2 (inkt)/trial designed with Merck
Technical Bottom
AADI longTrade levels are:
Entry price: $12.53
Take profit: $14.04
Stop loss: $11.96
Risk/reward: 2,65
$XBI target zone if, IF, risk-off returnsOn the weekly chart, price seemed to be breaking down from a channel and then reversed course to move higher. If this is a rubberband reaction and risk-off resumes, then this monthly frame shows a 2nd leg down that could move to 62-58.
Alternatively, if risk-on stays the course to continue January's rise, then price moves up to the 20ma, 96-100 area. Watch daily chart to see if price stays over 87-88.
GNOM A Good ETF that Captures the Genome & Biotech RevolutionBiotech in my opinion will be the biggest sector of growth in the 21st Century. Lot of value here in this ETF and it has the potential to explode in growth for a long time. Other good ETFs for this sector are ARKG IBB XBI. New highs in the next few years is my call on GNOM
BZYR: Potential long term investment - with riskI've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts:
1 - Introduction
2 - The historical battles
3 - Efficacy of a cancer treatment
4 - Summary
5 - The risk to reward for long term investors.
The above cannot possibly avoid referring to organisations and materials in the public domain - as matters of fact and truth before the courts.
Introduction:
The founder has discovered a treatment for cancers that cannot be treated by conventional treatments, that is better than anything out there at this time. The research has been in the public domain for the last 30-odd years. The discovery is called Antineoplastons - which is a combination of various peptides and other 'chemicals'.
Historical battles:
The research evidence for efficacy has not been faulted. The FDA (in the public domain) took the founder through 4 grand juries. The case failed at the Texas State Supreme Court, in an attempt to remove the founder's medical licence.
The whole story runs very deep back to the 1980s - but despite strenous efforts to shut down the treatment (and the founder), it persists to this day, through the endless legal battles. Staying within the 'House Rules' means that I am cautious not to breach.
In 1982 the FDA stated " never have and never will approve a new drug to an individual but only to a large pharmaceutical firm with unlimited finances ." Therefrom sprung one of the most severe fights in FDA history. dealings with the FDA commenced in 1983 at that point the FDA commenced a civil action to try to close the clinic and stop all patients from receiving the medicine before the judge in this case.
Before the judge in the 1983 court case had announced her ruling the FDA sends her a letter warning her in advance " if this court declines to grant the injunction sought by the government thus permitting continued manufacture and distribution of antineoplastons the government would then be obliged to pursue other less efficient remedies such as actions for seizure and condemnation of the drugs or criminal prosecution of individuals. "
Efficacy of cancer treatment with Antineoplastons:
Mainstream cancer research organisations will say " There is not enough reliable evidence to use it as a cancer treatment " or that the treatment is ' experimental '. But this is not true. If there has been an experiment, it was fully under the watch of the FDA, and the results are beyond belief for success.
Double-blind randomised controlled trials in Japan have proved the superior efficacy of the treatment (which is not 100% but far better than what exists).
Summary
Antineoplaston treatment has weathered all battles for over 30 years. It's not going away. It's survival suggests something novel and unique has been discovered. Why is this treatment surviving at all? Why all the battles against it? Those are matters for you to ponder.
The risk to reward for long term investors:
The weeky chart will show that BZYR (an OTC stock) is near rock bottom and possibly in an accummulation phase. Note carefully that OTC stocks are not on conventional exchanges like NYSE and NASDAQ.
The potential growth over a 5 year period could be significant in relation to a fixed risk of loss which should be an affordable one, if more research confirms it's specific kind of efficacy. This could be the next 'Amazon' of the biomedical world.
As always I emphasise the risk - and I am unable to provide tips on how to manage that. Disclaimers apply.
🟩 $RXDX - pilot here- I like the powerful move it is sustaining
- Volume signature is looking great
- Strong industry group
$LABP First Supply Test and VolumeCrazy volume on this one relative to it's history and .58 supply test and rejection but stock is still hovering above .4 resistance which is promising for longs.
I'm in at .3 and holding for .7 Target, to trim some along the way.
ENVB | So Many Bullish Divergences | LONGEnveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
$HTGMHolding 23.6 fib level, looking for a potential retest of 38.6 fib level at 1.46 and find support and confirm trend reversal back towards HOD.
Biotechs are on fire! Gossamer and upcoming event! Biotechnology is the favorite sector of one of our analysts, most of his portfolio consists of biotechs, and he himself claims that it is the cryptocurrency of the common stock market.
Why? Let's explain :
High risk/reward and high volatility.
Imagine this: you invest in a company that has no revenue or any specific product, yet you believe in the idea it promotes. You're taking giant risks because it's far from clear what to expect.
But for that you get a great opportunity to make a quick buck. In biotech, soaring by 20%, 30%, or even 100% is the absolute norm. But you have to approach it carefully, because if you fail, the reaction can be devastating.
Here is an example of successful investment in biotech companies:
Axsome Therapeutics
Ranks: 48.
The company recently grew by more than 30% after successful results from a clinical trial of its drug to treat agitation in Alzheimer's disease.
Cool? Absolutely.
Our analysts have found another attractive company with a catalyst in the coming days!
Its name is Gossamer Bio.
Ranks: 11
Financials are really weak, the Ranks system also gives it a low rating, but the coming catalyst could immediately change everything. In the coming days, the company is expected to present the data of phase 2 of its core drug GB002. Take a closer look at the company!
Biotechs are scam or great potential